Treat-to-Target

Real-world studies suggest that treat-to-target recommendations are often not fully implemented in routine clinical care. In the US CorEvitas RA registry, 61% of patients continued their initial RA treatment at 12 months despite inadequate response at 6 months. Treat-to-target care involves setting a clinical goal, measuring disease activity regularly, and adjusting therapy according to response. Treatment changes in routine care are influenced not only by disease activity but also by satisfaction, preferences, comorbidities, and tolerability. EULAR guidance recommends a treat-to-target strategy aiming for remission or low disease activity through regular monitoring and timely treatment adjustment. Treatment guidelines recommend treat-to-target strategies for rheumatoid arthritis.